Dow Jones
33.891,02 -34,99 (-0,10%) Nasdaq
11.887,45 -119,50 (-1,00%) Nikkei 225
27.738,32 +44,67 (+0,16%) EUR/USD
1,0741 +0,0010 (+0,10%) BTC-EUR
21.273,55 -316,95 (-1,47%) CMC Crypto 200
523,95 -1,18 (-0,22%)
Biocartis Group NV (0R72.L)
| Chiusura precedente | 1,7197 |
| Aperto | 1,7197 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 1,7200 - 1,7200 |
| Intervallo di 52 settimane | 1,7200 - 1,7200 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,51 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
PRESS RELEASE - REGULATED INFORMATION 31 January 2023, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 31 January 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of January 2023 a further portion of receivables due by the Company to Highbridge under the senior secured 'Facility Agreement' (as amended from time to time) ("First Lien Loan Agreement") conclud
- GlobeNewswire
Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES
PRESS RELEASE: REGULATED INFORMATION17 January 2023, 17:40 CET BIOCARTIS MEETS 2022 KEY OBJECTIVES Mechelen, Belgium, 17 January 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces that the Company has achieved its 2022 key business objectives focused on three performance indicators: Idylla™ product revenues, gross margins on product sales and operating cash burn. Based on non-audited numbers for 2022, Biocar
- GlobeNewswire
Press release Biocartis Group NV: Completion of Comprehensive Recapitalization Transactions
PRESS RELEASE: REGULATED INFORMATION16 January 2023, 17:40 CET Completion of Comprehensive Recapitalization Transactions Mechelen, Belgium, 16 January 2023 –Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART) is pleased to announce that the final steps in the previously announced comprehensive recapitalization transactions have been completed today. The initial holders of the Company's 4.50% new second lien secured convertible
